This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Melanoma	Serum amyloid A1 (SAA1; SAA); C-reactive protein (CRP)	<p>Proteomic analysis of human sera suggests that SAA could be a prognostic marker for melanoma progression. Mass spectrometric analysis of sera from 576 melanoma patients showed that high levels of the acute inflammatory response marker SAA in early-stage tumors were a predictor of poor prognosis ($p=0.043$). High levels of both SAA and another acute inflammatory response marker, CRP, correlated with the worst prognosis. Next steps include validating the results with larger, more precisely stratified sets of human samples and investigating the specific function of SAA in melanoma.</p> <p>SciBX 2(16); doi:10.1038/scibx.2009.656 Published online April 23, 2009</p>	Unpatented; licensing status not applicable	<p>Findeisen, P. <i>et al. J. Clin. Onc.</i>; published online March 23, 2009; doi:10.1200/JCO.2008.18.0554</p> <p>Contact: Selma Ugurel, University of Heidelberg, Heidelberg, Germany e-mail: ugurel_s@klinik.uni-wuerzburg.de</p>